Annovis Bio, Inc. (ANVS) Stock Price

ANVSStock
$1.7225.86%52W
Market Cap$73.28M
P/E
PEG Ratio
Div yield
Beta1.18

ANVS Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)-47.75%
Price vs S&P 500 (4W)-1.54%
VGM Score36.55

ANVS Earnings Surprise History

QuarterReport dateEPS estimateEPS actualSurprise
Q2 2026-$0.46-$0.40+13.04%(+$0.06)
Q1 2026-$0.35-$0.63-80.00%(-$0.28)
Q4 2025-$0.30-$0.39-30.00%(-$0.09)
Q3 2025-$0.37-$0.37+0.00%(+$0.00)
Q2 2025-$0.39-$0.32+17.95%(+$0.07)

ANVS Analyst Recommendations

May 2026
Jun 2026
Jul 2026
Aug 2026
4.10
4.13
4.13
4.11

Industry Peers — Pharmaceuticals(570)

SymbolValue ScoreGrowth ScoreMomentum ScorePrice
ANVSAnnovis Bio, Inc.
D$1.72
LLYEli Lilly & Co.DBC$1174.61
JNJJohnson & JohnsonDCB$268.04
ABBVABBVIE INC.DCB$255.48
MRKMerck & Co., Inc.DCB$148.35
NVSNovartis AGCCC$153.81
AZNAstraZeneca PLCCBC$162.70
NVONovo-Nordisk A/SBCC$45.61
ABTAbbott LaboratoriesCCC$112.47
PFEPfizer Inc.CDB$27.96
VRTXVertex Pharmaceuticals IncDCB$541.69

About Annovis Bio, Inc.

Annovis Bio is a clinical-stage biopharmaceutical company developing therapies for neurodegenerative diseases, primarily Alzheimer's and Parkinson's disease. Its pipeline includes Buntanetap for chronic neurodegeneration, ANVS405 for acute neurodegeneration, and ANVS301 for Alzheimer's disease.